位点特异性偶联的单甲基澳瑞他汀E和杜卡霉素抗PSMA抗体药物偶联物治疗PSMA表达肿瘤的表征
本研究将抗PSMA抗体D2B经糖基化学酶偶联杜卡霉素或单甲基澳瑞他汀E(MMAE),制备药物抗体比(DAR)为2和4的4种抗体药物偶联物(ADC)。在LS174T-PSMA荷瘤小鼠中,MMAE型ADC(D2B-DAR2-MMAE和D2B-DAR4-MMAE)显著抑制肿瘤生长并延长中位生存期,而杜卡霉素型ADC未显示此效应。
要点
- 位点特异性偶联保留了抗PSMA抗体的免疫反应性。
- MMAE型ADC显著抑制肿瘤生长并延长中位生存期,杜卡霉素型ADC未显示此效应。
- 111In-D2B-DAR2-MMAE在注射后3天肿瘤摄取最高,达119.7 ± 37.4 %ID/g。
核心结论
- 位点特异性偶联的抗PSMA ADC D2B-DAR2-MMAE和D2B-DAR4-MMAE有效靶向PSMA表达异种移植瘤,有效抑制PSMA表达肿瘤的生长,并显著延长小鼠生存期。
研究设计与样本
- 将抗PSMA抗体D2B的糖基经化学酶偶联杜卡霉素或MMAE,制备DAR为2和4的4种ADC。
- 在BALB/c裸鼠皮下LS174T-PSMA异种移植瘤模型中进行生物分布和小动物SPECT/CT显像(18.5 ± 2.6 MBq,25 μg 111In标记ADC)。
- 在LS174T-PSMA荷瘤小鼠中评估4种ADC的治疗效果。
主要发现
- 位点特异性偶联后抗PSMA抗体的免疫反应性得以保留。
- 生物分布显示所有药物肿瘤摄取高,111In-D2B-DAR2-MMAE组肿瘤摄取最高,注射后3天达119.7 ± 37.4 %ID/g。
- 小动物SPECT/CT可清晰显示注射111In-D2B、111In-D2B-DAR2-杜卡霉素、111In-D2B-DAR4-杜卡霉素、111In-D2B-DAR2-MMAE和111In-D2B-DAR4-MMAE小鼠的肿瘤。
- 与未偶联D2B或溶剂对照相比,MMAE型ADC(而非杜卡霉素型ADC)显著抑制肿瘤生长,并将中位生存期从13天(磷酸盐缓冲液)延长至DAR2和DAR4 ADC的20天和29天。
- D2B-DAR2-MMAE和D2B-DAR4-MMAE治疗后肿瘤倍增时间从3.5 ± 0.5天分别增至5.2 ± 1.8天和9.2 ± 2.1天。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Prostate cancer (PCa) is the most common cancer in men worldwide. In general, PCa responds poorly to chemotherapy. Therefore, antibody-drug conjugates (ADCs) have been developed to specifically deliver highly cytotoxic drugs to the tumor. Because the prostate-specific membrane antigen (PSMA) is overexpressed in PCa, it represents a promising target for ADC-based therapies. The aim of this study was to evaluate the therapeutic efficacy of site-specifically conjugated duocarmycin- and monomethyl auristatin E (MMAE)-based anti-PSMA ADCs with drug-to-antibody ratios (DARs) of 2 and 4. Methods: The glycan group of the anti-PSMA antibody D2B was chemoenzymatically conjugated with duocarmycin or MMAE. Preservation of the immunoreactivity of the antibody on site-specific conjugation was investigated in vitro. Biodistribution and small-animal SPECT/CT imaging (18.5 ± 2.6 MBq) with 25 μg of 111In-labeled ADCs were performed on BALB/c nude mice with subcutaneous PSMA-positive LS174T-PSMA xenografts. Finally, the therapeutic efficacy of the 4 different ADCs was assessed in mice with LS174T-PSMA tumors. Results: The immunoreactivity of the anti-PSMA antibody was preserved on site-specific conjugation. Biodistribution revealed high tumor uptake of all agents. The highest tumor uptake was observed in mice administered with 111In-D2B-DAR2-MMAE, reaching 119.7 ± 37.4 percentage injected dose per gram at 3 d after injection. Tumors of mice injected with 111In-D2B, 111In-D2B-DAR2-duocarmycin, 111In-D2B-DAR4-duocarmycin, 111In-D2B-DAR2-MMAE, and 111In-D2B-DAR4-MMAE could clearly be visualized with small-animal SPECT/CT. In contrast to unconjugated D2B or vehicle, treatment with either of the MMAE-based ADCs, but not with a duocarmycin-based ADC, significantly impaired tumor growth and prolonged median survival from 13 d (phosphate-buffered saline) to 20 and 29 d for DAR2 and DAR4 ADC, respectively. Tumor-doubling time increased from 3.5 ± 0.5 d to 5.2 ± 1.8 and 9.2 ± 2.1 d after treatment with D2B-DAR2-MMAE and D2B-DAR4-MMAE, respectively. Conclusion: The site-specifically conjugated anti-PSMA ADCs D2B-DAR2-MMAE and D2B-DAR4-MMAE efficiently targeted PSMA-expressing xenografts, effectively inhibited tumor growth of PSMA-expressing tumors, and significantly prolonged survival of mice.
引用
- Lütje S, Gerrits D, Molkenboer-Kuenen JD, et al. Characterization of Site-Specifically Conjugated Monomethyl Auristatin E- and Duocarmycin-Based Anti-PSMA Antibody-Drug Conjugates for Treatment of PSMA-Expressing Tumors. J Nucl Med. 2017. PMID: 29146698. doi:10.2967/jnumed.117.196279
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。